发布求助
搜索
全部
求助中
待确认
已完结
求助中
Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
用户Hk9Gh1
19小时前
10
我要应助
求助中
Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial
用户Hk9Gh1
19小时前
10
我要应助
求助中
Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration
用户Hk9Gh1
19小时前
10
我要应助
求助中
Re-evaluating antibody–drug conjugate linker stability: assessment, interpretation, and clinical translation
用户Hk9Gh1
19小时前
10
我要应助
求助中
Fovinaciclib for First-Line Therapy of Advanced Breast Cancer A Randomized Clinical Trial
用户Hk9Gh1
19小时前
10
我要应助
求助中
Body Mass Index and Nutritional Status With Immunotherapy Response in Head and Neck Cancer
用户Hk9Gh1
23小时前
10
我要应助
求助中
ZrO2制备方法研究进展
顺其自然
23小时前
10
我要应助
求助中
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
用户Hk9Gh1
2026-09-03
10
我要应助
求助中
Artificial Normality: How Conversational Agents’ Perceived Humanness Inhibits Error Attribution and Preserves Satisfaction
用户B6KjhZ
2026-09-02
10
我要应助
求助中
Therepresentation offunction in computer-based design
用户9ub1ja
2026-09-02
10
我要应助
求助中
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium
用户Hk9Gh1
2026-09-02
10
我要应助
求助中
Current advances and future directions of combined ICIs and TILs in solid tumors
用户Hk9Gh1
2026-09-02
10
我要应助
求助中
Trogocytosis-orchestrated CLDN18.2-“dressed” CD8+ T cells drive pancreatic cancer progression via glucose metabolic reprogramming-induced cytotoxicity debilitation and systematic immune senescence cascade
用户Hk9Gh1
2026-09-02
10
我要应助
求助中
Impact of KRAS Mutations and Co-Alterations on Outcomes in Stage III Nonsquamous NSCLC Treated With Chemoradiation and Immunotherapy
用户Hk9Gh1
2026-09-02
10
我要应助
求助中
Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma
用户Hk9Gh1
2026-09-02
10
我要应助
求助中
Impact of TP53, KEAP1 and STK11 mutations in localized-stage NSCLC: A European thoracic oncology platform lungscape project
用户Hk9Gh1
2026-09-02
10
我要应助
求助中
Targeting claudins in cancer
用户Hk9Gh1
2026-09-02
10
我要应助
求助中
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non–Small Cell Lung Cancer The HARMONi-A Randomized Clinical Trial
用户Hk9Gh1
2026-09-02
10
我要应助
求助中
Emerging trends in the global burden of colorectal cancer
用户Hk9Gh1
2026-09-02
10
我要应助
求助中
Antibody–drug conjugates in gynaecological cancers: opportunities and challenges
用户Hk9Gh1
2026-09-02
10
我要应助
首页
上一页
2
3
...
5
下一页
尾页